Advancement of Vaccines and Therapies for Henipaviruses

亨尼帕病毒疫苗和治疗的进展

• 批准号: 10581491
• 负责人: CHRISTOPHER C BRODER
• 金额: $ 563.18万
• 依托单位: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-20 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10581491
• 关键词: Adjuvant; Advanced Development; Animal Diseases; Animal Model; Animals; Antiviral Agents; Asia; Attenuated; Attenuated Vaccines; Australia; Bangladesh; Biological Warfare; Biology; Case Fatality Rates; Classification; Collaborations; Combined Modality Therapy; Communicable Diseases; Data; Data Management Resources; Disease; Disease Outbreaks; Dose; Drug Kinetics; Effectiveness; Ensure; Evaluation; Formulation; Freeze Drying; Future; Glycoproteins; Goals; Health; Hendra Virus; Henipavirus; Human; Immune; Individual; Infection; Infectious Diseases Research; Liquid substance; Livestock; Mammals; Monoclonal Antibodies; Morbidity - disease rate; Mutation; Nature; Nipah Virus; Paramyxovirus; Pathogenicity; Persons; Preparation; Prevention; Preventive vaccine; Procedures; Process; Production; Public Health; RNA Viruses; Recombinants; Research Institute; Research Project Grants; Respiratory Disease; Science; Subunit Vaccines; System; Testing; Therapeutic; Translational Research; Transportation; Tropism; United States Dept. of Health and Human Services; Vaccines; Viral; Viral Vaccines; Virus; Virus Diseases; Work; aluminum sulfate; clinical development; design; evaluation/testing; first responder; glycoprotein G; high risk; human disease; human monoclonal antibodies; immunogenicity; improved; mortality; nanoparticle; nervous system disorder; neutralizing antibody; nonhuman primate; novel; outbreak concern; particle; pathogenic virus; prevent; product development; programs; protective efficacy; transmission process; vaccine development; vaccine platform; vaccine strategy

Project Summary (OVERALL) The pathogenic henipaviruses (Nipah and Hendra) are distinguished among the paramyxoviruses by virtue of their uniquely broad tropism and impressive lethality. These viruses can infect animals across 6 orders of mammals, causing an often fatal disease in 11 species including humans. Nipah in Bangladesh is of particular concern, and outbreaks occur annually with near 100% case fatality rates and person-to-person transmission. Currently, there are no vaccines or therapeutics approved for human use. Nipah and Hendra are continuous infectious disease threats both to public health and to economically important livestock throughout South Asia and Australia. The henipaviruses are enveloped RNA viruses and their biology allows them to be synthetically produced, with high potential for misuse as agents of bioterror or biowarfare. There has been significant progress over the last decade in the development of vaccines and postexposure therapies for Nipah and Hendra. Preventive vaccines would have utility for lab workers, first responders or individuals at high risk exposure; but in the case of a biological attack or natural outbreak, a postexposure treatment would be the most practical approach. The henipavirus G and F glycoproteins are the major targets of neutralizing antibodies and the cornerstone of vaccine strategies. All three Research Projects (RP) in the Center focus on developing strategies effective against all pathogenic henipaviruses. RP1 focuses on the soluble Hendra G glycoprotein vaccine, RP2 focuses on human anti-henipavirus monoclonal antibodies, and RP3 focuses on recombinant Cedar virus-based vaccines. A unique aspect of this Center is that it includes both of the most- studied countermeasures that have shown the ability to provide complete pre- and post-exposure protection of nonhuman primates against Nipah/Hendra infection. The level of certain advancements among the RPs is a major strength and advantage of our Center. The primary objective of the Advancement of Vaccines and Therapies for Henipaviruses Center is to perform pivotal studies that will facilitate the development of products used for the prevention and treatment of Nipah and Hendra infections. The cooperation among the three RPs, Administrative Core, human monoclonal antibody Core and Biosafety Level (BSL)-4 Core is built into the Center by design, as all components work together to provide broadly effective countermeasures. Quality system data management will be employed in both the preparation of advanced stage test articles and in the conduct of animal studies. Relevance (OVERALL) Nipah and Hendra, are highly pathogenic viruses and threats to both human and livestock health. They are available in nature, can be synthetically generated and easily produced and disseminated, with the potential for high mortality rates and major public heath impact. There are no countermeasures approved for human use. This Center focuses on the advanced development of the most promising antivirals, including the only strategy shown to offer postexposure protection of nonhuman primates against henipaviruses.

项目总结（总体）

项目成果

Vaccines to Emerging Viruses: Nipah and Hendra.

新兴病毒的疫苗：Nipah和Hendra。

• DOI: 10.1146/annurev-virology-021920-113833
• 发表时间: 2020-09-29
• 期刊: Annual review of virology
• 影响因子: 11.3
• 作者: Amaya M;Broder CC
• 通讯作者: Broder CC

Serological evidence of a pararubulavirus and a betacoronavirus in the geographically isolated Christmas Island flying-fox (Pteropus natalis).

• DOI: 10.1111/tbed.14579
• 发表时间: 2022-09
• 期刊: TRANSBOUNDARY AND EMERGING DISEASES
• 影响因子: 4.3
• 作者: Pulscher, Laura A.;Peel, Alison J.;Rose, Karrie;Welbergen, Justin A.;Baker, Michelle L.;Boyd, Victoria;Low-Choy, Samantha;Edson, Dan;Todd, Christopher;Dorrestein, Annabel;Hall, Jane;Todd, Shawn;Broder, Christopher C.;Yan, Lianying;Xu, Kai;Peck, Grantley R.;Phalen, David N.
• 通讯作者: Phalen, David N.

Structure and design of Langya virus glycoprotein antigens.

琅琊病毒糖蛋白抗原的结构与设计。

• DOI: 10.1101/2023.08.20.554025
• 发表时间: 2023
• 期刊: bioRxiv : the preprint server for biology
• 作者: Wang,Zhaoqian;McCallum,Matthew;Yan,Lianying;Sharkey,William;Park,Young-Jun;Dang,HaV;Amaya,Moushimi;Person,Ashley;Broder,ChristopherC;Veesler,David
• 通讯作者: Veesler,David